311 related articles for article (PubMed ID: 22777336)
1. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
2. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors use and change in bone mineral density.
Arj A; Razavi Zade M; Yavari M; Akbari H; Zamani B; Asemi Z
Int J Rheum Dis; 2016 Sep; 19(9):864-8. PubMed ID: 27242025
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
[TBL] [Abstract][Full Text] [Related]
5. Sedentary behavior does not predict low BMD nor fracture-population-based Canadian Multicentre Osteoporosis Study.
Guðmundsdóttir SL; Berger C; Macdonald H; Adachi JD; Hopman WM; Kaiser SM; Kovacs CS; Davison KS; Morin SN; Goltzman D; ; Prior JC
J Bone Miner Res; 2024 Apr; 39(3):231-240. PubMed ID: 38477796
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
8. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
9. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
[TBL] [Abstract][Full Text] [Related]
11. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and vertebral fractures in men.
Legrand E; Chappard D; Pascaretti C; Duquenne M; Rondeau C; Simon Y; Rohmer V; Basle MF; Audran M
Osteoporos Int; 1999; 10(4):265-70. PubMed ID: 10692973
[TBL] [Abstract][Full Text] [Related]
15. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density.
Fattahi MR; Niknam R; Shams M; Anushiravani A; Taghavi SA; Omrani GR; Mahmoudi L
Risk Manag Healthc Policy; 2019; 12():349-355. PubMed ID: 31853206
[TBL] [Abstract][Full Text] [Related]
16. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
17. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.
Jamal SA; Goltzman D; Hanley DA; Papaioannou A; Prior JC; Josse RG
Osteoporos Int; 2009 May; 20(5):737-44. PubMed ID: 18800179
[TBL] [Abstract][Full Text] [Related]
18. Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos).
Cooke-Hubley S; Gao Z; Mugford G; Kaiser SM; Goltzman D; Leslie WD; Davison KS; Brown JP; Probyn L; Lentle B; Prior JC; Kovacs CS
Arch Osteoporos; 2019 Apr; 14(1):49. PubMed ID: 31037359
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.
Chen W; Johnson KM; FitzGerald JM; Sadatsafavi M; Leslie WD
Arch Osteoporos; 2018 Oct; 13(1):116. PubMed ID: 30374631
[TBL] [Abstract][Full Text] [Related]
20. Accelerated bone mineral loss following a hip fracture: a prospective longitudinal study.
Dirschl DR; Henderson RC; Oakley WC
Bone; 1997 Jul; 21(1):79-82. PubMed ID: 9213011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
